CD20-CD19 cCAR T cell therapy (iCell Gene Therapeutics) |
|
Phase Ⅰ |
iCell Gene Therapeutics |
B-cell lymphoma, Leukemia |
Details
|
Anti-CD20 CART-transduced T cells (Cellular Biomedicine Group) |
CART-20; CBM-C20.1; CBM-CD20 1;,CART 20; CBM C20.1; CBM CD20 1;,CART20; CBMC20.1; CBMCD20 1; |
Phase Ⅱ |
General Hospital of the People's Liberation Army, Cellular Biomedicine Group |
B-cell lymphoma, Leukemia |
Details
|
Humanized monoclonal antibody targeting CD20 (Shanghai Pharma) |
B-001 |
Phase Ⅰ |
Shanghai Pharma |
Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) |
Details
|
64Cu-DOTA-rituximab (Stanford University) |
64Cu-DOTA-Rituximab; Cu64-DOTA-rituximab; Cu-64 Rituximab; [64Cu]DOTA-rituximab |
Phase Ⅰ |
Stanford University |
Non-Hodgkin's lymphoma (NHL) |
Details
|
GB-4542 (Gliknik) |
GB-4542 |
Preclinical |
Gliknik |
Autoimmune diseases, Cancer |
Details
|
Rituximab biosimilar (Fred Hutchinson Cancer Research Center) |
|
Phase Ⅰ |
Fred Hutchinson Cancer Research Center |
Multicentric Castleman's Disease (MCD), Kaposi's sarcoma |
Details
|
Plamotamab |
XmAb-13676 |
Phase Ⅰ |
Xencor, Novartis |
Chronic lymphocytic leukemia (CLL), B-cell lymphoma |
Details
|
Rituximab biosimilar (Gedeon Richter) |
RGB-03 |
Phase Ⅰ |
Gedeon Richter, STADA Arzneimittel, Mochida |
Rheumatoid arthritis (RA) |
Details
|
FBTA-05 |
Bi-20; FBTA-05 |
Phase Ⅱ |
Trion Research |
Lymphoblastic leukaemia, B-cell lymphoma |
Details
|
Rituximab biosimilar (Lonza/Teva Pharmaceutical Industries) |
TL-011 |
Phase Ⅲ |
Lonza, Teva Pharmaceutical Industries |
Diffuse large B cell lymphoma, Rheumatoid arthritis (RA) |
Details
|
TRS-005 |
TRS-005,TRS005; TRS 005 |
Phase Ⅰ |
Zhejiang Teruisi Pharmaceutical |
Non-Hodgkin's lymphoma (NHL) |
Details
|
H02 |
H-02,H02; H 02 |
Phase Ⅰ |
Shandong Xinshidai Pharmaceutical |
Non-Hodgkin's lymphoma (NHL) |
Details
|
CD20-directed CAR-T cell therapy (Tongji Hospital) |
C-CAR066 |
Phase Ⅰ |
Tongji Hospital, Cellular Biomedicine Group |
B-cell lymphoma |
Details
|
Recombinant chimeric anti-CD20 monoclonal antibody (Sinocelltech) |
SCT-400,SCT400 |
BLA Filing |
Sinocelltech, China Shijiazhuang Pharmaceutical Group/CSPC |
Non-Hodgkin's lymphoma (NHL) |
Details
|
Rituximab biosimilar (Lupin) |
|
Preclinical |
Lupin |
Rheumatoid arthritis (RA) |
Details
|
CD20/CD22 dual Targeted CAR T-cell therapy (Zhejiang University) |
|
Phase Ⅰ |
Zhejiang University |
Lymphoid Hematological Malignancies |
Details
|
MB-CART20.1 (Miltenyi Biotec) |
|
Phase Ⅱ |
Miltenyi Biotec |
Non-Hodgkin's lymphoma (NHL) |
Details
|
Rituximab biosimilar (Hisun Pharma/Beijing Mabworks Biotech) |
|
Phase Ⅲ |
Hisun Pharm, Beijing Mabworks Biotech |
Diffuse large B cell lymphoma |
Details
|
Rituximab conjugate (BioIntegrator) |
CON-4619 |
Phase Ⅰ |
BioIntegrator |
Non-Hodgkin's lymphoma (NHL) |
Details
|
Recombinant human anti-CD20 monoclonal antibody (Sailemin Biotech) |
|
IND Filing |
Shenzhen Sailemin Biological Technology |
Unspecified |
Details
|
Pretarget lymphoma therapy (Poniard) |
|
Phase Ⅰ |
Poniard Pharmaceuticals |
Non-Hodgkin's lymphoma (NHL) |
Details
|
Recombinant chimeric anti-CD20 antibody (Shanghai Institute of Biological Products) |
|
Phase Ⅲ |
Shanghai Institute of Biological Products |
Diffuse large B cell lymphoma |
Details
|
MB-106 |
MB-106 |
Phase Ⅱ |
Fred Hutchinson Cancer Research Center, Mustang Bio |
Non-Hodgkin's lymphoma (NHL) |
Details
|
Ocrelizumab biosimilar (CinnaGen) |
|
Phase Ⅲ |
CinnaGen |
Multiple sclerosis (MS) |
Details
|
IMM-0306 |
IMM-0306,IMM0306 |
Phase Ⅰ |
ImmuneOnco |
Lymphoma, Non-Hodgkin B-cell lymphomas |
Details
|
Recombinant Fc-glycosylated anti-CD20 monoclonal antibody (Bio-Thera Solutions) |
BAT-4306F |
Phase Ⅰ |
Bio-Thera Solutions |
Chronic lymphocytic leukemia (CLL), Multiple sclerosis (MS), Rheumatoid arthritis (RA), Non-Hodgkin's lymphoma (NHL) |
Details
|
Anti-CD20 allogeneic CAR-T cell therapy (Nanjing Medical University) |
LUCAR-20S |
Phase Ⅰ |
Nanjing Medical University |
Mantle cell lymphoma (MCL), Small lymphocytic lymphoma (SLL), B-cell lymphoma, Follicular lymphoma |
Details
|
Dual specificity CD19 and CD20 or CD22 CAR-T cell (Chinese PLA General Hospital) |
|
Phase Ⅱ |
General Hospital of the People's Liberation Army |
B-cell lymphoma, Leukemia |
Details
|
PF-5212374 |
PF-5212374; TRU-015,PF5212374; TRU015,PF 5212374; TRU 015 |
Phase Ⅱ |
Emergent, Pfizer |
Rheumatoid arthritis (RA), Non-Hodgkin B-cell lymphomas |
Details
|
4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) |
4SCAR-T |
Phase Ⅱ |
Shenzhen Geno-Immune Medical Institute |
B-cell malignancies |
Details
|
Glofitamab |
RO-7082859; RG-6026,RO7082859; RG6026,RO 7082859; RG 6026 |
Phase Ⅲ |
Roche |
Diffuse large B cell lymphoma |
Details
|
MT-3724 |
MT-3724 |
Phase Ⅱ |
Molecular Partners, Banner MD Anderson Cancer Center, Molecular Templates |
Diffuse large B cell lymphoma, Non-Hodgkin's lymphoma (NHL) |
Details
|
Mosunetuzumab |
RO-7030816; RG-7828; BTCT-4465A |
Phase Ⅱ |
Genentech, Chugai |
Diffuse large B cell lymphoma, Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) |
Details
|
CD19/CD20 bispecific chimeric antigen receptor (CAR)-T cell therapy (Jonsson Comprehensive Cancer Center) |
|
Phase Ⅰ |
UCLAs Jonsson Comprehensive Cancer Center |
Chronic lymphocytic leukemia (CLL), B-cell lymphoma |
Details
|
Rituximab biosimilar (Innovent Biologics) |
IBI-301 |
BLA Filing |
Innovent Biologics, Lilly |
Diffuse large B cell lymphoma |
Details
|
Rituximab biosimilar (Shenzhen Main Luck Pharmaceuticals) |
|
Phase Ⅰ |
Shenzhen Main Luck Pharmaceuticals |
Rheumatoid arthritis (RA), Lymphoma |
Details
|
HSK-III-001 |
HSK-III-001 |
Phase Ⅰ |
Haisco Pharmaceutical Group |
hematological malignancies |
Details
|
Rituximab biosimilar (Boehringer Ingelheim) |
BI-695500 |
Phase Ⅲ |
Boehringer Ingelheim |
Follicular lymphoma, Rheumatoid arthritis (RA) |
Details
|
Recombinant anti-CD20 humanized monoclonal antibody (Shanghai Pharma) |
|
Phase Ⅰ |
Shanghai Pharma |
Lymphoma |
Details
|
Allogeneic anti-CD20 CAR-T cell therapy (Precision BioSciences) |
PBCAR-20A,PBCAR20A |
Phase Ⅱ |
Precision BioSciences |
Small lymphocytic lymphoma (SLL), Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) |
Details
|
IGN-002 |
IGN-002 |
Phase Ⅰ |
ImmunoGen, The Leukemia & Lymphoma Society, Valor Biotherapeutics |
Non-Hodgkin's lymphoma (NHL) |
Details
|
Odronextamab |
REGN-1979 |
Phase Ⅱ |
Regeneron Pharmaceutical, Sanofi |
Lymphoblastic leukaemia, Chronic lymphocytic leukemia (CLL), B-cell lymphoma, Follicular lymphoma, Non-Hodgkin's lymphoma (NHL) |
Details
|
Rituximab biosimilar (AXXO) |
|
Phase Not Specified |
AXXO |
Leukemia, Rheumatoid arthritis (RA) |
Details
|
Chimeric antigen receptor T-cell therapy (Fred Hutchinson Cancer Research Center) |
|
Phase Ⅱ |
Fred Hutchinson Cancer Research Center |
Mantle cell lymphoma (MCL), Diffuse large B cell lymphoma, Chronic lymphocytic leukemia (CLL), Waldenström's macroglobulinemia (WM), Follicular lymphoma, Marginal zone lymphoma, Non-Hodgkin B-cell lymphomas |
Details
|
MRG001 |
MRG-001,MRG001 |
Phase Ⅰ |
Shanghai Miracogen |
Non-Hodgkin's lymphoma (NHL) |
Details
|
Rituximab biosimilar (JHL Biotech) |
JHL-1101 |
Phase Ⅲ |
JHL Biotech, Sanofi |
Diffuse large B cell lymphoma, Rheumatoid arthritis (RA) |
Details
|
DI-Leu16-IL2 |
DI-Leu16-IL2 |
Phase Ⅱ |
Merck Serono, Alopexx Oncology, Provenance Biopharmaceuticals |
Non-Hodgkin's lymphoma (NHL) |
Details
|
Recombinant humanized monoclonal antibody MIL62 |
|
Phase Ⅱ |
Beijing Mabworks Biotech, Innocare |
Follicular lymphoma, Marginal zone lymphoma |
Details
|
Recombinant anti-CD20 monoclonal antibody (Geneky Biotech) |
|
IND Filing |
Genekey Biotech (Chengdu) |
Rheumatoid arthritis (RA), Lymphoma |
Details
|
BVX20-CD20 antibody (Biocon/Vaccinex) |
BVX-20; BVX20-MAb |
Phase Ⅱ |
Biocon, Vaccinex |
Non-Hodgkin's lymphoma (NHL) |
Details
|
Humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (Fujian Medical University) |
|
Phase Ⅰ |
Fujian Medical University |
Diffuse large B cell lymphoma |
Details
|
Rituximab biosimilar (Zhejiang Teruisi Pharmaceutical) |
TRS001 |
Phase Ⅰ |
Zhejiang Teruisi Pharmaceutical |
Lymphoma |
Details
|
177-Lu-DOTA-rituximab (University of Basel) |
|
Phase Ⅱ |
University Hospital Basel |
Cancer |
Details
|
Rituximab biosimilar (International Biotech Center Generium) |
GNR-006 |
Phase Ⅰ |
International Biotech Center Generium |
B-cell lymphoma |
Details
|
Radiolabeled anti-CD20 antibody (NeoRx) |
|
Phase Ⅰ |
Poniard Pharmaceuticals |
B-cell lymphoma, Cancer |
Details
|
Anti-CD3/anti-CD20 bispecific antibody-armed activated T-cells (Barbara Ann Karmanos Cancer Institute) |
|
Phase Ⅰ |
Barbara Ann Karmanos Cancer Institute, National Cancer Institute |
Lymphoma |
Details
|
Rituximab biosimilar (CTTQ Pharma) |
TQB-2303 |
Phase Ⅲ |
Chiatai Tianqing (CTTQ) |
Diffuse large B cell lymphoma, Non-Hodgkin's lymphoma (NHL) |
Details
|
EX-103 |
EX-103,EX103 |
Preclinical |
ExcelMab |
Chronic lymphocytic leukemia (CLL), Rheumatoid arthritis (RA), Non-Hodgkin's lymphoma (NHL) |
Details
|
MK-8808 |
MK-8808,MK 8808,MK8808 |
Phase Ⅲ |
Merck Sharp & Dohme |
Follicular lymphoma, Rheumatoid arthritis (RA) |
Details
|
Anti-CLEVER-1 antibodies (Faron Pharmaceuticals) |
FP-1115; FP-1302; FP-1304; FP-1305 |
Phase Ⅱ |
Faron |
Solid tumours |
Details
|
MB-CART2019.1 |
MB-CART2019.1 |
Phase Ⅱ |
Miltenyi Biotec |
Small lymphocytic lymphoma (SLL), Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) |
Details
|
BCD-132 |
BCD-132 |
Phase Ⅱ |
Biocad |
Multiple sclerosis (MS) |
Details
|
BAT-4406F |
BAT-4406F; BAT-4406 |
Phase Ⅰ |
Bio-Thera Solutions |
Neuromyelitis optica (NMO) |
Details
|
Rituximab biosimilar (Nichi-Iko Pharmaceutical/Aprogen) |
AP-056 |
BLA Filing |
Nichi-Iko Pharmaceutical, Aprogen |
Autoimmune diseases, Transplant rejection, Leukemia, Non-Hodgkin's lymphoma (NHL) |
Details
|
Anti-CD20 CAR T-cell therapy (Southwest Hospital Chongqing) |
|
Phase Ⅱ |
Southwest Hospital Chongqing |
Diffuse large B cell lymphoma |
Details
|
TAT-014 |
BCIA-07; TAT-014 |
Phase Ⅰ |
TOT Biopharm |
Mantle cell lymphoma (MCL), Solid tumours |
Details
|
Rituximab biosimilar (Samsung) |
SAIT-101 |
Phase Ⅲ |
Samsung BioLogics |
Rheumatoid arthritis (RA) |
Details
|
PRO-131921 |
PRO-131921 |
Phase Ⅱ |
Genentech |
Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) |
Details
|
Anti-CD19 and anti-CD20 CAR-T cell therapy (Medical College of Wisconsin) |
|
Phase Ⅱ |
Medical College of Wisconsin |
B-cell malignancies |
Details
|
Rituximab biosimilar (BioIntegrator) |
|
Phase Ⅰ |
BioIntegrator |
Rheumatoid arthritis (RA), Cancer |
Details
|
Rituximab biosimilar (Shanghai CP Guojian Pharmaceutical) |
CMAB-304 |
BLA Filing |
Shanghai CP Guojian |
Diffuse large B cell lymphoma |
Details
|
Ocaratuzumab |
AME-133; AME-133v; LY-2469298 |
Phase Ⅱ |
Applied Molecular Evolution, MENTRIK Biotech |
Follicular lymphoma, Non-Hodgkin's lymphoma (NHL) |
Details
|
CD19/CD20 bispecific CAR-T cells (Henan Cancer Hospital) |
|
Phase Ⅰ |
Henan Cancer Hospital |
B-cell lymphoma |
Details
|
Bendamustine Hydrochloride/Rituximab |
|
Phase Ⅰ |
1Globe Biomedical |
B-cell lymphoma |
Details
|
Rituximab/Paclitaxel |
AR-160 |
Phase Ⅰ |
Mayo Clinic |
Non-Hodgkin B-cell lymphomas |
Details
|
CD20 x CD3 bispecific antibody (IGM Biosciences) |
IGM-2323 |
Phase Ⅰ |
IGM Biosciences |
Mantle cell lymphoma (MCL), Diffuse large B cell lymphoma, Follicular lymphoma, Marginal zone lymphoma, Non-Hodgkin's lymphoma (NHL) |
Details
|
Recombinant anti-CD20 chimeric monoclonal antibody (Livzon Group) |
LZM-002 |
Phase Ⅰ |
Livzon Group |
Diffuse large B cell lymphoma, CD20-positive follicular lymphoma, Non-Hodgkin's lymphoma (NHL) |
Details
|
ABP-798 |
ABP-798; APB-798 |
BLA Filing |
Amgen, Allergan |
Rheumatoid arthritis (RA), Non-Hodgkin's lymphoma (NHL) |
Details
|
Anti-CD20 CAR T-cell therapy (Shanghai Longyao Biotechnology) |
|
Phase Ⅱ |
Shanghai Longyao Biotechnology |
Refractory diffuse large B cell lymphoma |
Details
|
Rituximab biosimilar (Siam Bioscience) |
|
BLA Filing |
Siam Bioscience |
B-cell lymphoma |
Details
|
Anti-CD20 monoclonal antibodies (Verenium) |
|
Phase Not Specified |
BASF, MMRGlobal |
Non-Hodgkin's lymphoma (NHL) |
Details
|
Anti-CD20 monoclonal antibody (BioMedics) |
BM-ca |
Phase Ⅰ |
BioMedics |
Non-Hodgkin's lymphoma (NHL) |
Details
|
B-cell lymphoma gene therapy (City of Hope) |
|
Phase Ⅰ |
City of Hope National Medical Center |
B-cell lymphoma |
Details
|
Iodine 131 tositumomab |
TST/I131-TST |
Withdrawn |
GlaxoSmithKline |
Non-Hodgkin's lymphoma (NHL) |
Details
|
Anti-CD20 CAR-T cell therapy (Wuhan Bio-Raid) |
|
Phase Not Specified |
Wuhan Bio-Raid Biotechnology |
B-cell malignancies |
Details
|
SBI-087 |
PF-05230895; PF-5230895; SBI-087 |
Phase Ⅱ |
Emergent, Pfizer |
Rheumatoid arthritis (RA) |
Details
|
Rituximab biosimilar (Chia Tai Tianqing Pharmaceutical Group) |
TQB-2303 |
Phase Ⅱ |
Chiatai Tianqing (CTTQ) |
Non-Hodgkin's lymphoma (NHL) |
Details
|
Rituximab biosimilar (Hualan Biological Engineering) |
WBP-263,WBP263; WBP 263 |
Phase Ⅲ |
Hualan Biological Engineering |
Non-Hodgkin's lymphoma (NHL) |
Details
|
Rituximab biosimilar (Genor Biopharma) |
GB-241,GB241; GB 241 |
Phase Ⅲ |
Genor Biopharma, Nanjing Yoko Biological |
Diffuse large B cell lymphoma, Non-Hodgkin's lymphoma (NHL) |
Details
|
Anti-CD3 anti-CD20 bispecific antibody (Genmab) |
GEN-3013 |
Phase Ⅱ |
Genmab |
hematological malignancies |
Details
|
Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein (Fred Hutchinson Cancer Research Center) |
|
Phase Ⅰ |
Fred Hutchinson Cancer Research Center, National Cancer Institute |
Mantle cell lymphoma (MCL), Diffuse large B cell lymphoma, Burkitt's lymphoma, Non-Hodgkin B-cell lymphomas |
Details
|
Veltuzumab |
hA20; IMMU-106 |
Phase Ⅱ |
Immunomedics |
Immune thrombocytopenic purpura, Non-Hodgkin's lymphoma (NHL) |
Details
|
CD19/CD20 Dual-CAR-T cell therapy (HeBei Yanda hospital) |
|
Phase Ⅰ |
HeBei Yanda hospital |
B-cell lymphoma |
Details
|
IDM-4 |
IDM-4 |
Phase Ⅱ |
Takeda |
Chronic lymphocytic leukemia (CLL) |
Details
|
Ublituximab |
R-603; LFB-R603; EMAB-6; TG-1101; TGTX-1101; TG-1303 |
Phase Ⅲ |
TG Therapeutics, ILDONG PHARMACEUTICAL |
Chronic lymphocytic leukemia (CLL), Multiple sclerosis (MS) |
Details
|
Rituximab biosimilar (Bionovis/The Instituto) |
|
Phase Not Specified |
Bionovis, The Instituto Vital Brazil |
Granulomatosis with polyangiitis, Chronic lymphocytic leukemia (CLL), Rheumatoid arthritis (RA), Non-Hodgkin's lymphoma (NHL) |
Details
|
Rituximab biosimilar (Mabion) |
MabionCD-20 |
BLA Filing |
Mabion |
Diffuse large B cell lymphoma, Rheumatoid arthritis (RA) |
Details
|
CD20 CAR-T cell therapy (Shanghai Longyao Biotechnology) |
|
Phase Ⅰ |
Shanghai Longyao Biotechnology |
Non-Hodgkin's lymphoma (NHL) |
Details
|
CD20-specific-T-cells |
|
Phase Ⅰ |
Fred Hutchinson Cancer Research Center, National Cancer Institute |
Waldenström's macroglobulinemia (WM), Leukemia, Lymphoma |
Details
|
Rituximab biosimilar (Zhejiang hisun pharmaceutical) |
HS-006 |
Phase Ⅱ |
Hisun Pharm |
Diffuse large B cell lymphoma |
Details
|